Efficacy of initial combination with belimumab in newly diagnosed childhood-onset lupus nephritis: a single-centre historical control study Authors: Yinv Gong, Shuhua Liu, Haimei Liu, Yu Shi, Yifan Li, Wanzhen Guan, Qiaoqian Zeng, Qianying Lv, Xiaomei Zhang, Qijiao Wei, Jing Chen, Qian Shen, Hong Xu, Li Sun Published: 2024 ABSTRACT AbstractObjectiveTo explore the efficacy of initial treatment of newly diagnosed childhood-onset lupus nephritis (cLN) with combination of belimumab and either cyclophosphamide, mycophenolate mofetil, tacrolimus or multitargeted therapy.MethodsA historical control study was conducted on children aged 5–17 years with newly diagnosed cLN. All patients recruited met the 2012 Systemic Lupus International Collaborating Clinics and/or 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for SLE, and the 2003 International Society of Nephrology/Renal Pathology Society histopathological criteria for LN. The primary endpoint was primary efficacy renal response (PERR) at 12 months, and secondary endpoints included complete renal response (CRR), lupus low disease activity state (LLDAS) and remission (Definitions of Remission in Systemic Lupus Erythematosus (DORIS)) at 12 months, changes of SLE Disease Activity Index (SLEDAI) and dose of glucocorticoid (GC).ResultsA total of 101 patients were included with 38 patients in the belimumab group and 63 patients in the standard immunotherapy group. There were no statistically significant differences between the two groups at baseline. At 12 months, compared with the standard immunotherapy group, more patients in the belimumab group had a higher PERR (97.1% vs 80.0%, χ2=3.965, p=0.046), CRR (94.1% vs 76.6%, χ2=4.679, p=0.031), LLDAS (75.0% vs 18.6%, χ2=27.84, p<0.001) and DORIS (34.4% vs 11.9%, χ2=6.626, p=0.01). The belimumab group had faster and greater reductions in SLEDAI and dose of GC (p<0.05), with a significantly higher proportion of patients with dose of GC ≤7.5 mg/day (82.9% vs 30.4%, χ2=19.737, p<0.001). In the standard immunotherapy group, 4 patients (6.3%) experienced a decline in estimated glomerular filtration rate of 30% or more at 12 months, while no patients in the belimumab group experienced worsening of renal function. There were no serious adverse events reported in two groups, and there was no significant difference in the occurrence of infection between the two groups.ConclusionThis study reported for the first time the effectiveness of combined belimumab therapy in a Chinese cohort of patients with cLN. The strategy of initial combination with belimumab helps achieve treatment targets earlier and faster GC tapering. And initial combination therapy in children with cLN with high disease activity may yield more significant benefits.Keywords: Lupus Nephritis; Biological Products; Lupus Erythematosus, Systemic WHAT IS ALREADY KNOWN ON THIS TOPIC WHAT THIS STUDY ADDS This study firstly reported the effectiveness of initial combination with belimumab in newly diagnosed childhood-onset lupus nephritis (cLN), achieving Primary Efficacy Renal Response, Complete Renal Response, Lupus Low Disease Activity State and Definitions of Remission in Systemic Lupus Erythematosus faster and more extensively. This study firstly reported the effectiveness of initial combination with belimumab in newly diagnosed childhood-onset lupus nephritis (cLN), achieving Primary Efficacy Renal Response, Complete Renal Response, Lupus Low Disease Activity State and Definitions of Remission in Systemic Lupus Erythematosus faster and more extensively. More than 80% patients reduced glucocorticoid dose to less than 7.5 mg/day at 12 months. More than 80% patients reduced glucocorticoid dose to less than 7.5 mg/day at 12 months. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY The study highlights the potential benefits of initial combination with belimumab in cLN with high disease activity, upfront combination (Step down) strategy is more suitable in childhood-onset SLE/LN. The study highlights the potential benefits of initial combination with belimumab in cLN with high disease activity, upfront combination (Step down) strategy is more suitable in childhood-onset SLE/LN. Introduction Childhood-onset SLE (cSLE) is a common autoimmune disease that often affects multiple systems and organs with the presence of various autoantibodies. The prevalence of SLE in China is 30–70 cases per 100 000 people, with cSLE accounting for 10%–20% of total SLE cases. Compared with adult SLE, cSLE is more severe, characterised by a rapid onset, high disease activity, rapid progression of organ damage and higher incidence of renal involvement. Kidney involvement occurs in approximately 50%–80% of children with SLE.1 The treatment of SLE aims to achieve complete disease remission or lupus low disease activity state (LLDAS) involving all organs, while minimising complications and drug toxicity to improve survival rates.2 With aggressive immunotherapy, the prognosis of lupus nephritis (LN) in children has significantly improved, with 63.8%–82.7% of paediatric patients achieving clinical remission. However, recurrence still occurs in 35.3%–69.6% of patients,1 with even approximately 15% progressing to end-stage renal disease (ESRD), which remains a major cause of mortality in cSLE. With the continuous advance of the pathogenesis of SLE/LN, new medications such as belimumab have been developed and applied in clinical practice. The phase III clinical trials of belimumab in adult SLE (Belimumab in Subjects with Systemic Lupus Erythematosus (BLISS)-52, BLISS-76) conducted in 2011 demonstrated the efficacy and safety of belimumab combined with standard immunotherapy.3 In 2020, the clinical trials of belimumab for active LN (BLISS-LN) and active cSLE (The Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy (PLUTO)) were published, indicating similar benefits and safety results in adult LN and active cSLE.4,6 However, few cohort studies reported on the use of belimumab in childhood-onset LN (cLN).7 The objective of this study is to evaluate the difference in efficacy between the initial treatment of belimumab combined with standard immunotherapy and standard immunotherapy alone for paediatric patients with newly diagnosed LN in a real-world setting. Methods Study design This study is a single-centre, open-label, retrospective cohort historical control study. The study focused on children with newly diagnosed LN admitted to the Department of Rheumatology, Children’s Hospital of Fudan University from 1 January 2016 to 31 December 2022. Ethical approval for the off-label use of belimumab in the treatment of cSLE/LN was obtained in November 2019, and belimumab was introduced for patients with active cSLE/LN from 1 April 2020. Patients who received initial treatment with belimumab in combination with standard immunotherapy between 1 April 2020 and 31 December 2022 were included in the belimumab group. While patients who received only standard immunotherapy between 1 January 2016 and 31 March 2020 were included in standard immunotherapy group as the historical control group. Patients or members of the public were not involved in the design, or conduct, or reporting, or dissemination plans of the research. Study subjects Inclusion criteria Age 5–17 years, any gender. Age 5–17 years, any gender. Met the classification criteria for SLE established by the Systemic Lupus International Collaborating Clinics (SLICC) in 20128 or the European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) in 2019.9 Met the classification criteria for SLE established by the Systemic Lupus International Collaborating Clinics (SLICC) in 20128 or the European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) in 2019.9 Met the diagnostic criteria for LN according to the ‘Diagnosis and Treatment Guidelines for Lupus Nephritis in Children’ formulated by the Paediatric Nephrology Group of the Chinese Medical Association in 201010 or the ‘Evidence-based Guidelines for the Diagnosis and Treatment of Lupus Nephritis’ in 2016,11 and underwent renal biopsy with LN histological classification consistent with the International Society of Nephrology/Renal Pathology Society 2003 classification.12 The renal biopsies were classified by two pathologists separately and reviewed by a senior renal pathologist to confirm the diagnosis of renal pathology. Met the diagnostic criteria for LN according to the ‘Diagnosis and Treatment Guidelines for Lupus Nephritis in Children’ formulated by the Paediatric Nephrology Group of the Chinese Medical Association in 201010 or the ‘Evidence-based Guidelines for the Diagnosis and Treatment of Lupus Nephritis’ in 2016,11 and underwent renal biopsy with LN histological classification consistent with the International Society of Nephrology/Renal Pathology Society 2003 classification.12 The renal biopsies were classified by two pathologists separately and reviewed by a senior renal pathologist to confirm the diagnosis of renal pathology. The parents or guardians of the patients provided written informed consent for the use of belimumab and standard immunotherapy, and agreed to comply with the follow-up requirements. The parents or guardians of the patients provided written informed consent for the use of belimumab and standard immunotherapy, and agreed to comply with the follow-up requirements. Exclusion criteria Time interval between baseline and diagnosis exceeding 60 days. Time interval between baseline and diagnosis exceeding 60 days. Lack of clinical data or the follow-up duration was less than 6 months. Lack of clinical data or the follow-up duration was less than 6 months. Grouping and treatment regimens Belimumab group On the basis of standard immunotherapy, we added the belimumab treatment regimen. Belimumab was administered intravenously at a dose of 10 mg/kg at weeks 0, 2 and 4, followed by a dose of 10 mg/kg every 4 weeks. The standard immunotherapy regimens are described in the ‘Standard Immunotherapy Group’ section. Standard immunotherapy group Standard immunotherapy included the use of glucocorticoids (GCs), hydroxychloroquine in combination with immunosuppressive agents such as cyclophosphamide (CYC), mycophenolate mofetil (MMF), Tacrolimus (FK506) or multitargeted therapy (MMF and FK506). Glucocorticoids Prednisone at a dose of 1.0–2.0 mg/kg/day, with a maximum daily dose of 60 mg/day (or equivalent). One to two courses of intravenous pulses of methylprednisolone (15–30 mg/kg (not to exceed 1000 mg) for 3 days as one course) may be chosen based on the patient’s condition during induction. Cyclophosphamide Monthly intravenous infusion of 500–750 mg/m2, with a maximum of 1 g per month, for a total of about six infusions (maximum cumulative dose of 6 g). Mycophenolate mofetil Oral administration at a dose of 20–40 mg/kg/day, divided into two doses (12-hour intervals), with a maximum oral dose of 1.5 g/day. Dose adjustment based on drug concentration monitoring and patients’ condition (note: MMF- area under the curve (AUC) target concentration is 40–60 mg*hour/L). Tacrolimus Oral administration at a dose of 0.05–0.1 mg/kg/day, divided into two doses, with a maximum oral dose of 3 mg/day. Dose adjustment based on drug concentration monitoring and patients’ condition (note: the target concentration for FK506 is 5–10 ng/µL). Patients were required to gradually taper GCs based on the treating specialist physician and clinical response, including improvement of SLE Disease Activity Index (SLEDAI), and extrarenal and renal response comprehensively. ACE inhibitors or angiotensin receptor blockers, as well as anticoagulant/antiplatelet therapy such as low-molecular-weight heparin, aspirin or clopidogrel, were also allowed. Outcome The primary outcome is the primary efficacy renal responses (PERR)5 at 12 months. PERR was defined as a urine protein-to-creatinine ratio (UPCR) ≤0.7 mg/mg, a decrease in estimated glomerular filtration rate (eGFR) ≤20% from baseline or eGFR ≥60 mL/min/1.73 m2, and no rescue therapy due to treatment failure. Rescue therapy was considered for patients who needed to re-increase the dose of GCs, or received additional immunosuppressive agents (except topical agents) beyond the induction and maintenance regimens due to LN relapse or persistent non-remission, non-response of LLDAS. The secondary outcomes include: (1) Complete renal response (CRR)5 at 12 months. CRR was defined as UPCR <0.5 mg/mg, eGFR ≥90 mL/min/1.73 m2 or a decrease in eGFR ≤10% from baseline, and no rescue therapy due to treatment failure. (2) LLDAS and Definitions of Remission in Systemic Lupus Erythematosus (DORIS) at 12 months of treatment. LLDAS2 was defined as a SLEDAI ≤4, no disease activity in major organs, no new disease activity compared with previous assessments, Physician’s Global Assessment (PGA) Score ≤1, prednisolone dose ≤7.5 mg/day, and standard maintenance doses of immunosuppressive agents and biologics. DORIS2 was defined as SLEDAI Score =0 (excluding serological parameters), PGA Score <0.5, prednisolone dose ≤5 mg/day, and standard maintenance doses of immunosuppressive agents and biologics. (3) Proportion of daily dose of GC ≤7.5 mg/day and 5 mg/day at 12 months. (4) Changes in SLEDAI and daily dose of GC during the 24 months of treatment. (5) Change trends in UPCR, 24-hour urine protein, albumin, eGFR and complement levels during the 24 months of treatment. (6) Incidence of decrease of eGFR ≥30% and LN recurrence until the follow-up endpoint. The study’s follow-up endpoint was the last follow-up visit or follow-up until 31 December 2023. All patients, including the belimumab group and the standard immunotherapy group, would be prospectively evaluated for SLEDAI Scores, PGA Scores as part of routine clinical care at each follow-up time point, and these were recorded in electronic medical record systems and individual follow-up files, along with the dose of GCs. Definitions and explanations eGFR was calculated using the modified Schwartz formula: eGFR (ml/(min·1.73 m2)) = K × height (cm)/serum creatinine (Scr) (μmol/L), where K=36.5. eGFR was calculated using the modified Schwartz formula: eGFR (ml/(min·1.73 m2)) = K × height (cm)/serum creatinine (Scr) (μmol/L), where K=36.5. Definition of LN recurrence:13 (1) Proteinuric recurrence was defined as an increase in 24-hour urine protein >1 g after complete remission or an increase >2 g after partial remission. (2) Nephritic recurrence was defined as an increase in serum creatinine ≥30% (or a decrease in eGFR ≥10%), presence of ≥10 red blood cells per high-power field in urine (of glomerular origin), and meeting either of the above two criteria. Definition of LN recurrence:13 (1) Proteinuric recurrence was defined as an increase in 24-hour urine protein >1 g after complete remission or an increase >2 g after partial remission. (2) Nephritic recurrence was defined as an increase in serum creatinine ≥30% (or a decrease in eGFR ≥10%), presence of ≥10 red blood cells per high-power field in urine (of glomerular origin), and meeting either of the above two criteria. Statistical analysis Data were analysed using SPSS V.26.0 software, graphs were generated using GraphPad Prism V.9.5. Normally distributed continuous data are presented as mean±SD and were compared using t-tests. Non-normally distributed continuous data are presented as median (IQR) or M (Q1, Q3) and were compared using non-parametrical tests. Categorical data are presented as numbers (percentages) (n (%)) and were compared using χ2 tests. Cox proportional hazards regression models were used to compare differences in PERR, CRR, LLDAS and DORIS between the two groups. Mixed linear models were used to compare within-group and between-group differences in repeated variables over time. A two-sided value of p<0.05 was considered statistically significant. Results General information From 1 January 2016 to 31 December 2022, a total of 209 newly diagnosed patients with cLN were consecutively diagnosed in our centre. A total of 101 patients with cLN were included in this study, with 38 patients in the belimumab group and 63 patients in the standard immunotherapy group (figure 1). Flow chart of patient selection in the clinical study of cLN. cLN, childhood-onset lupus nephritis; pts, patients. Baseline characteristics There were no statistically significant differences between the belimumab group and the standard immunotherapy group in terms of age, renal function (eGFR, proportion of acute kidney injury), urinary protein (24-hour urinary protein, proportion of massive proteinuria), renal histopathological type, disease activity (SLEDAI), proportion of low complement, distribution of autoantibodies, systemic involvement and baseline immunotherapy regimens (including daily dose of GC, proportion of methylprednisolone pulse, composition of immunosuppressive agents). There were statistically significant differences in gender, UPCR and serum albumin (table 1). The median follow-up time was 18 (15, 24) months in the belimumab group and 24 (21, 24) months in the standard immunotherapy group. Table 1Baseline characteristics of the belimumab group and the standard immunotherapy groupVariableBLM (n=38)ST (n=63)T/ZP valueGender (male, n (%))4 (10.5)17 (27.0)3.8980.048Age (years)11.5±2.411.4±2.20.0350.972Height (cm)147.8±12.4142.7±20.71.1910.237Weight (kg)42.1±12.337.3±11.91.9230.057Renal pathology (n (%))3.1220.210 II11 (28.9)9 (14.3) III or IV or III/IV+V24 (63.2)48 (76.2) V3 (7.9)6 (9.5)eGFR (mL/min/1.73 m2)88.7±28.582.3±47.8−0.6540.514AKI (N (%))12 (31.6)26 (41.3)0.9490.330Serum albumin (g/L)30.1±6.925.9±6.92.9050.005UPCR (mg/mg)1.42 (0.5, 5.5)4.5 (1.3, 12.0)−2.440.01524-hour urinary protein (g)0.99 (0.5, 5.3)2.19 (0.9, 5.8)1.9100.056 ≥50 mg/kg11 (28.9)24 (38.1)0.8760.349Immunological parameters (n (%)) Low complement33 (91.7)54 (85.7)0.0250.874 Positive of anti-dsDNA antibody28 (73.7)42 (66.7)0.5490.459 Positive of antinuclear antibodies35 (92.1)57 (90.5)1.000 Positive of anti-Sm antibody7 (18.4)12 (20.3)0.0060.938SLEDAI20 (14,24)21 (18, 25)−1.4720.141 Mild (5–9)4 (10.5)1 (1.6)3.9970.136 Moderate (10–14)6 (15.8)10 (15.9) Severe (≥15)28 (73.7)52 (82.5)Systemic involvement (n (%)) Fever13 (34.2)12 (19.0)2.9260.087 Serositis9 (23.7)14 (22.2)0.0290.865 Mucocutaneous18 (47.4)36 (57.1)0.9100.340 Musculoskeletal12 (31.6)10 (15.9)3.4320.064 Haematological30 (78.9)48 (76.2)0.1020.749 Gastrointestinal4 (10.5)5 (7.9)0.726 Respiratory5 (13.2)3 (4.8)0.149 Neurological2 (5.3)6 (9.5)0.707Treatment regimen (n (%)) Initial glucocorticosteroid dose56.4±7.456.5±7.1−0.140.889 Hydroxychloroquine36 (94.7)61 (96.8)0.63 Immunosuppressive agents5.6390.125 CYC to MMF23 (60.5)45 (71.4) CYC to FK5061 (2.6)5 (7.9) MMF12 (31.6)8 (12.7) FK5062 (5.3)5 (7.9) Methylprednisolone pulse therapy24 (63.2)50 (79.4)3.1790.075 Acute renal replacement therapy2 (5.3)10 (15.9)0.202 Blood purification2 (5.3)4 (6.3)1.000 ACE inhibitors19 (50.0)35 (55.6)0.2940.588 Anticoagulation/antiplatelet drugs29 (76.3)52 (82.5)0.5780.447AKIacute kidney injuryBLMbelimumab groupCYCcyclophosphamideeGFRestimated glomerular filtration rateFK506tacrolimusMMFmycophenolate mofetilSLEDAISLE Disease Activity IndexSTstandard immunotherapy groupUPCRurine protein-to-creatinine ratio Baseline characteristics of the belimumab group and the standard immunotherapy group AKIacute kidney injuryBLMbelimumab groupCYCcyclophosphamideeGFRestimated glomerular filtration rateFK506tacrolimusMMFmycophenolate mofetilSLEDAISLE Disease Activity IndexSTstandard immunotherapy groupUPCRurine protein-to-creatinine ratio Otherwise, the baseline demographic data of the 28 synchronous patients who declined belimumab after 1 April 2020 were similar to those of the belimumab treatment group (online supplemental table 1). Outcomes Primary outcome The results with respect to the primary and major secondary outcomes are provided in table 2. At 12 months, more patients achieved PERR in the belimumab group than in the standard immunotherapy group (97.1% (33/34) vs 80.0% (48/60), χ2=3.965, p=0.046). Starting at 3 months, at each visit, more patients receiving belimumab had a PERR than those receiving immunotherapy only (p<0.05) (figure 2A), and the probability of patients sustaining PERR through 24 month was higher (HR=0.631, 95% CI 0.415 to 0.959, p=0.031) in the belimumab group (figure 2C). Table 2The primary and major secondary outcomes in the belimumab group and the standard immunotherapy groupOutcomeBLMST χ 2 OR, 95% CIP valuePrimary outcome PERR at 12 months97.1% (33/34)80.0% (48/60)3.9650.121 (0.15 to 0.978)0.046Major secondary outcome CRR at 12 months94.1% (32/34)76.6% (46/60)4.6790.205 (0.044 to 0.966)0.031 LLDAS at 12 months75.0% (24/32)18.6% (11/59)27.840.076 (0.027 to 0.215)<0.001 DORIS at 12 months34.4% (11/32)11.9% (7/59)6.6260.257 (0.088 to 0.753)0.01 Dose of GC ≤7.5 mg/day82.9% (29/35)30.4% (17/56)23.7490.090 (0.032 to 0.257)<0.001 Dose of GC ≤5 mg/day42.9% (15/35)19.6% (11/56)5.6880.326 (0.127 to 0.834)0.017BLMbelimumab groupCRRcomplete renal responseDORISDefinitions of Remission in SLEGCglucocorticoidLLDASlupus low disease activity statePERRprimary efficacy renal responseSTstandard immunotherapy group The primary and major secondary outcomes in the belimumab group and the standard immunotherapy group BLMbelimumab groupCRRcomplete renal responseDORISDefinitions of Remission in SLEGCglucocorticoidLLDASlupus low disease activity statePERRprimary efficacy renal responseSTstandard immunotherapy group Renal responses and disease activity over time. BLM, belimumab group; CRR, complete renal response; DORIS, Definitions of Remission in SLE; LLDAS, lupus low disease activity state; PERR, primary efficacy renal response; ST, standard immunotherapy group. Secondary outcomes At 12 months, significantly more patients in the belimumab group had CRR (94.1% (32/34) vs 76.6% (46/60), χ2=4.679, p=0.031), LLDAS (75.0% (24/32) vs 18.6% (11/59), χ2=27.84, p<0.001) and DORIS (34.4% (11/32) vs 11.9% (7/59), χ2=6.626, p=0.01) than in the standard immunotherapy group. The probability of maintaining CRR (HR=0.571, 95% CI 0.373 to 0.875, p=0.010), LLDAS (HR=0.393, 95% CI 0.244 to 0.632, p<0.001) and DORIS (HR=0.332, 95% CI 0.197 to 0.561, p<0.001) through 24 months was significantly higher in the belimumab group (figure 2B, D, E and F). Both the groups showed a significant decrease in SLEDAI Scores compared with baseline (p<0.05). The SLEDAI Scores decreased continuously within the first 12 months (p<0.05) in the belimumab group, and within the first 15 months (p<0.05) in the standard immunotherapy group in contrast, and both groups remained stable later. In the belimumab group, the descend range of SLEDAI Scores was significantly greater, and SLEDAI Scores sustained significantly lower after 12–18 months (p<0.05) (figure 3A). SLEDAI and dose of GCs over time. **p<0.01; *p<0.05. BLM, belimumab group; GC, glucocorticoid; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; ST, standard immunotherapy group. Similarly, the belimumab group and the standard immunotherapy group showed a decrease in daily dose of GC within 12 months and 18 months, respectively (p<0.05), followed by stable maintenance. Within the first 15 months, the daily dose of GC in the belimumab group was consistently lower than that in the standard immunotherapy group (p<0.05), especially within the first 6 months (figure 3B). Compared with the standard immunotherapy group, at 12 months of treatment, the proportions of patients in the belimumab group with GC dosage below 7.5 mg/day (82.9% (29/35) vs 30.4% (17/56), χ=23.749, p<0.001) and below 5 mg/day (42.9% (15/35) vs 19.6% (11/56), χ=5.688, p=0.017) were both significantly higher (table 2). Changes of clinical indicators Both groups showed a significant decrease in UPCR and 24-hour urinary protein, increase of serum albumin and eGFR compared with baseline within the first 3 months to 6 months (p<0.05) (figure 4A–D). There were no statistically differences between the two groups in 24-hour urinary protein, UPCR, serum albumin from 3 months to 15 months (p>0.05). Notably, the belimumab group had lower values of UPCR and 24-hour urinary protein at 21 months, and higher levels of albumin at 18 months and 21 months, possibly due to relapse factors in the standard immunotherapy group. There were no statistically differences at each time point of eGFR (figure 4D). However, four patients in the standard immunotherapy group experienced a decrease in eGFR of ≥30% at 12 months; one patient even progressed to ESRD at 2 years and required chronic peritoneal dialysis at about 2.5 years after onset, while there were no such patients in the belimumab group. There was no mortality in both groups. Changes of clinical indicators over time. BLM, belimumab group; eGFR, estimated glomerular filtration rate; ST, standard immunotherapy group; UPCR, urine protein-to-creatinine ratio. Complement levels in both groups increased within the first 3 months and there were no statistically significant differences in the ratio of low complement between the two groups at each point (figure 4E). Disease relapse and rescue therapy In the belimumab group, there were no patients with LN relapse until the follow-up endpoint, and no patients required rescue therapy. However, in the standard immunotherapy group, 10 patients required rescue therapy, 3 patients among them experienced relapse at a median of 18 months. Five patients received methylprednisolone pulse therapy, three combined with rituximab and two received adjustments with multitargeted therapy. Safety There were no infusion-related reactions and mental and neurological diseases occurred in the belimumab group. The infection profile for the belimumab group was similar to that of the standard immunotherapy group (table 3). 23 patients (60.5%) in the belimumab group reported various degrees of infection, mainly with acute upper respiratory tract infection, bronchitis and toenail paronychia, while 39 patients (61.9%) in the standard immunotherapy group experienced different infections, with acute upper respiratory tract infection, urinary tract infection and pneumonia being the most common. No serious infections occurred in either group. As for the SLICC Damage Index (SDI), one patient with ESRD in the standard immunotherapy group evaluated a score of 1, while other patients in the standard immunotherapy group and the whole belimumab group scored 0. Table 3Infection-related adverse eventsInfection (n (%))BLM (n=38)ST (n=63) Oral candida infection3 (7.9)3 (4.8) Gum abscess01 (1.6) Acute upper respiratory tract infection5 (13.2)12 (19.0) Bronchitis4 (10.5)2 (3.2) Pneumonia3 (7.9)6 (9.5) Urinary tract infection2 (5.3)11 (17.5) Acute gastroenteritis1 (2.6)3 (4.8) Toenail paronychia4 (10.5)1 (1.6) Skin abscesses1 (2.6)0 Total23 (60.5)39 (61.9)Aetiologies Mycoplasma pneumoniae03 (4.8) A/B influenza viruses2 (5.3)0 Helicobacter pylori1 (2.6)0 Herpes zoster01 (1.6) Epstein-Barr virus03 (4.8) Cytomegalovirus1 (2.6)0BLMbelimumab groupSTstandard immunotherapy group Infection-related adverse events BLMbelimumab groupSTstandard immunotherapy group Discussion Intravenously belimumab has been approved by the US Food and Drug Administration (FDA) for the treatment of active adult SLE (March 2011) and cSLE aged 5 years and above (April 2019, priority approval). It has also been approved for the treatment of active LN in adults receiving standard therapy (December 2020) and in patients aged 5–17 years old with active cLN (July 2022). In China, belimumab has been approved by the National Medical Products Administration for the treatment of active SLE in adults (July 2019) and children (≥5 years old) (December 2020), as well as for active adult LN (February 2022). At our centre, ethical approval for off-label use of belimumab in cSLE/LN was obtained in November 2019. We successfully treated the first patient, a child with neuropsychiatric lupus and refractory recurrent seizures, using belimumab in combination with standard immunotherapy.14 The patient achieved disease remission and maintained a state of remission, allowing successful tapering of GCs without significant infection. Afterwards, we gradually used belimumab for children with various refractory and severe SLE, including those with LN, and we also observed impressive therapeutic benefits. In recent years, there has been a gradual emergence of biologic agents for SLE, leading to changes in treatment strategies, and the diagnostic and treatment guidelines for LN have been continuously updated. The 2023 EULAR updated management guidelines for adult SLE included belimumab as a treatment option for LN.15 The 2024 Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for LN also recommends belimumab in combination with traditional immunotherapy as one of the treatment options for active LN of class III/IV with or without class V.16 17 Although belimumab has been approved by the FDA for cLN, evidence of its efficacy in cLN is very limited, and there is almost no cohort study of belimumab in cLN.18 Considering the high prevalence, high disease activity and prognostic impact of LN in cSLE, our centre proposed the scientific hypothesis since 2020 that initiating treatment of belimumab in combination with standard immunotherapy for newly diagnosed cLN might expedite achieving treatment targets and protect organ function. Therefore, we conducted this study, which was designed as a single-centre, open-label, historical control study. The BLISS-LN Study5 used PERR and CRR as renal response indicators, which are comprehensive evaluation criteria that consider urine protein levels, renal function, and the use of rescue therapy. The BLISS-LN Study demonstrated that the combination of belimumab with standard therapy improved the 52-week PERR compared with standard therapy alone (47% vs 35%). Additionally, it showed even greater advantages in the Asian population (62% vs 37%).19 In this cLN cohort study, 97.1% and 94.1% of patients in the belimumab group achieved PERR and CRR, respectively, at 12 months, which was significantly higher than the control group. The SDI/ACR Damage Index20 is a validated assessment tool for evaluating organ damage in SLE. It has been reported to be associated with increased mortality in SLE, with a 34% higher risk of death for each additional point on the SDI.21 Floris et al22 reported that in their cohort of newly diagnosed patients with SLE (at 6 months of treatment), those who achieved LLDAS and DORIS early had a significantly lower proportion of patients with SDI Score ≥1 at 18 months compared with those who did not. Furthermore, a systematic review indicated a positive correlation between DORIS, LLDAS and a lower risk of organ damage, relapse, mortality, and hospitalisation rates, suggesting that early achievement of LLDAS and DORIS can improve prognosis.23 In this study, the belimumab group had a significantly higher proportion of patients reaching LLDAS (70.5%) and DORIS (34.3%) at 12 months compared with the control group. These results are consistent with those from a Chinese multicentre study on belimumab for active cSLE (of which our centre was one of the participating centres), which reported LLDAS of 70.3% and DORIS of 29.7% at 12 months.24 The results were slightly better than those from a retrospective study on Chinese adults with LN, which reported an LLDAS of 50%–60% at 9–12 months.25 26 Adult SLE currently has a relatively clear GC tapering strategy, with the 2023 EULAR recommendation of reducing to 5 mg/day at 12 weeks.14 However, there is no unified GC tapering strategy for children internationally. Due to the challenges of achieving remission, and the high relapse rate in paediatric SLE/LN, GC tapering is often more conservative and slower than in adult SLE. In this cohort, all patients were newly diagnosed with cLN, and at baseline, the dosage of GC was nearly prednisolone 2 mg/kg (not exceeding 60 mg per day). Surprisingly, the combined use of belimumab can lead to a faster reduction in disease activity of newly diagnosed cSLE/cLN, making it possible for a rapid and significant reduction in GC dose. In the belimumab group, 82.9% and 42.9% of patients achieved doses of GC ≤7.5 mg/day and ≤5 mg/day, respectively, at 12 months, which was significantly higher than in the control group. These results are similar to the aforementioned data in adults and children. Comparing the effectiveness of belimumab or placebo in combination with standard therapy for active SLE, such as PLUTO (paediatric phase II), BLISS-52, BLISS-76, BLISS-belimumab efficacy in patients from North East Asia (NEA) and EMBRACE (adult phase III) studies,27 it was found that the efficacy of belimumab in paediatric patients and adult patients with SLE was similar, and the SLE Responder Index 4 (SRI-4) response rate was significantly higher in patients with a baseline SLEDAI Score of ≥10 compared with those with ≤9, suggesting that belimumab provides greater benefits to patients with higher disease activity. Recently, Tani et al28 conducted a retrospective cohort prospective data analysis of 102 patients with SLE from the single-centre Pisa SLE cohort who received combination therapy with belimumab. Among them, 22 cases (21.6%) received belimumab as initial treatment. Compared with patients who received belimumab later, the two groups had similar proportions of achieving LLDAS. However, the group that received belimumab as initial treatment showed a faster reduction in GC dosage, and lower GC doses at 6 months and 12 months. The study suggested that initial combination therapy with belimumab, even prioritising it over standard immunotherapy, could lead to faster GC tapering and lower GC doses. Although existing studies have confirmed the efficacy of belimumab for active and refractory cSLE,29 there is currently a lack of efficacy data on the initial combination of belimumab in paediatric LN. In addition to renal involvement, newly diagnosed cLN often presents with multiple extrarenal systems involvement, resulting in overall high disease activity. In our study, the baseline SLEDAI Score of patients with newly diagnosed cLN was 20.0 (17.0, 24.0), which was higher than the disease activity of adult patients with LN in the BLISS-LN Study (SLEDAI 12.3±5.0)5 and those in the Chinese multicentre cohort of active cSLE (median SLEDAI 10–11).6 Combination with high disease activity makes treatment of paediatric LN more challenging. We observed that more patients with initial combination therapy achieved PERR, CRR, LLDAS and DORIS at 12 months with lower daily dose of GC. Therefore, the advantages of early combination therapy with belimumab are more pronounced in patients with cLN with high disease activity. Using it as an initial treatment in newly diagnosed patients can help achieve renal remission and overall disease control at an earlier stage. It can also facilitate the rapid reduction of GC dosage, minimising the potential toxic effects of medications and preventing organ damage. LN has a prolonged course, with approximately a third of cases experiencing relapse, and each relapse leads to significant loss of renal units, with 15% of patients progressing to chronic kidney disease (CKD) stage 5.1 30 The adult BLISS-LN clinical study demonstrated that belimumab in combination with standard immunotherapy can reduce the risk of eGFR decline and decrease LN relapse by approximately 55%.5 Early combination therapy improves renal remission and creates a treatment time window to prevent renal unit loss and prolong renal lifespan in young patients.31 In our study, the belimumab group had no eGFR decline or relapse at the study endpoint, while four patients experienced an eGFR decline of ≥30% by 12 months, and three patients experienced LN relapse by 18 months in the standard immunotherapy group. Considering the protective effect of belimumab on renal function and its ability to reduce relapse rates, long-term follow-up is needed to further elucidate the long-term benefits of belimumab in preventing LN relapse and reducing risk of CKD in patients with cLN. Due to the limitations of being a single-centre retrospective study, there is an imbalance in clinical data and sample sizes, which restricts the statistical results, inevitably leading to potential bias. Additionally, the observation period was relatively short (12–24 months), so further long-term follow-up is needed to determine whether long-term use of belimumab can reduce LN relapse and protect renal function. Questions regarding the appropriate timing, treatment duration and long-term benefits of belimumab in cLN treatment warrant more large-scale, multicentre, prospective, high-quality clinical studies and/or real-world studies for further exploration. Furthermore, long-term longitudinal cohort studies are needed to provide more clarity on the safety aspects of belimumab in cLN. Conclusion This study reports for the first time the effectiveness of combined belimumab therapy in a Chinese cohort of patients with cLN. The strategy of initial combination with belimumab helps to improve early response rates within the ‘window of opportunity’, minimising glomerular loss and GC dose as much as possible. Additionally, initial combination therapy may yield more significant benefits in children with high disease activity in cLN. The upfront combination (Step down) strategy is more suitable in cSLE/LN. supplementary material Acknowledgements The authors thank all the patients who participated in their study. Footnotes Funding: This work was supported by the Children's Hospital of Fudan University (2020ZBDL14). Provenance and peer review: Not commissioned; externally peer reviewed. Patient consent for publication: Consent obtained from parent(s)/guardian(s) Ethics approval: This study involves human participants and was approved by the Research Ethics Committee of Children’s Hospital of Fudan University (Approval No. FuErLunShen (2022)134). Participants gave informed consent to participate in the study before taking part. Patient and public involvement: Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research. Contributor Information Yinv Gong, Email: gongyinv@163.com. Shuhua Liu, Email: 1640533136@qq.com. Haimei Liu, Email: liu__hm@163.com. Yu Shi, Email: shiyu_821008@163.com. Yifan Li, Email: liyifan0815@163.com. Wanzhen Guan, Email: gwzleo@163.com. Qiaoqian Zeng, Email: 570749186@qq.com. Qianying Lv, Email: lvqianying2711@163.com. Xiaomei Zhang, Email: 810176112@qq.com. Qijiao Wei, Email: weiqijiao@126.com. Jing Chen, Email: cjcjcjs@163.com. Qian Shen, Email: shenqianjing@aliyun.com. Hong Xu, Email: hxu@shmu.edu.cn. Li Sun, Email: lillysun@263.net. Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information. References Associated Data Supplementary Materials Data Availability Statement All data relevant to the study are included in the article or uploaded as supplementary information.